Louis Haenel, DO
Endocrinology, Diabetes & Metabolism · Charleston, SCNPI 1669412995
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $341,401 of the $376,897 with a category attached, or 90.6%. 52 manufacturers reported payments, led by Novo Nordisk at 56.0% of the total. Reporting peaked in 2022 at $82,633 and has fallen 56.0% since, to $36,339 in 2025. Among endocrinology, diabetes & metabolism clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,051 payments — averaging $358.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$211K
- Lilly USA, LLC$146K
- AstraZeneca$7K
- Amgen$3K
- Abbott$2K
- Medtronic$1K
- plus $6K from 46 others
What the payments were for
- Speaking & faculty fees$341,40191%
- Travel & lodging$15,3524%
- Food & beverage$19,9785%
- Education$1070%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$137,303
- RYBELSUS$102,293
- Ozempic$90,218
- Tresiba$12,296
- FARXIGA$5,510
- Xultophy 100/3.6$2,633
- TEPEZZA$2,542
- CeQur Simplicity$331
- FREESTYLE LIBRE 3$308
- FreeStyle Libre$265
- Omnipod$158
- Minimed 770G System$157
- CRYSVITA$124
- NEXLIZET$122
- NEXLETOL$122
- TZIELD$115
How this compares
$376,897 in reported general payments places this provider in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 282 | $426,473 |
| OzempicSemaglutide | 276 | $416,406 |
| Tresiba Flextouch U-100Insulin Degludec | 185 | $172,623 |
| JardianceEmpagliflozin | 125 | $168,784 |
| TrulicityDulaglutide | 69 | $128,612 |
| FarxigaDapagliflozin Propanediol | 71 | $88,981 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $72,997 |
| RybelsusSemaglutide | 30 | $72,323 |
| JanuviaSitagliptin Phosphate | 29 | $34,489 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $33,974 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $28,384 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 12 | $18,917 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $16,987 |
| Novolog FlexpenInsulin Aspart | 49 | $16,470 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $15,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $146,061 | $564,696379 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $211,214 | $497,198335 claims |
| Boehringer IngelheimJardiance | $470 | $168,784125 claims |
| AstraZenecaFarxiga | $6,503 | $88,98171 claims |
| MerckJanuvia | $49 | $34,48929 claims |
| AbbVieSynthroid | $411 | $14,994171 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $223 | $9,886785 claims |
| Sanofi-aventis U.S. LLCLantus | $528 | $2,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Charleston
- Beatrice HullCharleston$214K
- Jaimin PatelCharleston$37K
- Jyotika FernandesCharleston$12K
- Kathie HermayerCharleston$4K
- Eliana MilazzoCharleston$2K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.